Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control
Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although t...
Saved in:
| Published in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 8; no. 6; p. 2050 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.06.2020
|
| Subjects: | |
| ISSN: | 2213-2201, 2213-2201 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently.
To test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions.
Two AECT versions with a recall period of 4 weeks (AECT-4wk) and 3 months (AECT-3mo) were tested for their internal consistency and test-retest reliability, convergent and known-groups validity as well as screening accuracy in 81 patients with RA with bradykinin-mediated angioedema, mast cell mediator-mediated angioedema, or idiopathic angioedema.
Both AECT versions showed excellent internal consistency reliability with a Cronbach alpha value of more than 0.85 and test-retest reliability with an intraclass correlation coefficient greater than 0.9. The convergent validity of both AECT versions was high. Both tools showed strong correlations with anchors of disease control, angioedema frequency, and health-related quality of life. A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.
The AECT is the first valid and reliable patient-reported outcome measure to assess disease control in patients with RA. |
|---|---|
| AbstractList | Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently.
To test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions.
Two AECT versions with a recall period of 4 weeks (AECT-4wk) and 3 months (AECT-3mo) were tested for their internal consistency and test-retest reliability, convergent and known-groups validity as well as screening accuracy in 81 patients with RA with bradykinin-mediated angioedema, mast cell mediator-mediated angioedema, or idiopathic angioedema.
Both AECT versions showed excellent internal consistency reliability with a Cronbach alpha value of more than 0.85 and test-retest reliability with an intraclass correlation coefficient greater than 0.9. The convergent validity of both AECT versions was high. Both tools showed strong correlations with anchors of disease control, angioedema frequency, and health-related quality of life. A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.
The AECT is the first valid and reliable patient-reported outcome measure to assess disease control in patients with RA. Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently.BACKGROUNDRecurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently.To test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions.OBJECTIVETo test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions.Two AECT versions with a recall period of 4 weeks (AECT-4wk) and 3 months (AECT-3mo) were tested for their internal consistency and test-retest reliability, convergent and known-groups validity as well as screening accuracy in 81 patients with RA with bradykinin-mediated angioedema, mast cell mediator-mediated angioedema, or idiopathic angioedema.METHODSTwo AECT versions with a recall period of 4 weeks (AECT-4wk) and 3 months (AECT-3mo) were tested for their internal consistency and test-retest reliability, convergent and known-groups validity as well as screening accuracy in 81 patients with RA with bradykinin-mediated angioedema, mast cell mediator-mediated angioedema, or idiopathic angioedema.Both AECT versions showed excellent internal consistency reliability with a Cronbach alpha value of more than 0.85 and test-retest reliability with an intraclass correlation coefficient greater than 0.9. The convergent validity of both AECT versions was high. Both tools showed strong correlations with anchors of disease control, angioedema frequency, and health-related quality of life. A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.RESULTSBoth AECT versions showed excellent internal consistency reliability with a Cronbach alpha value of more than 0.85 and test-retest reliability with an intraclass correlation coefficient greater than 0.9. The convergent validity of both AECT versions was high. Both tools showed strong correlations with anchors of disease control, angioedema frequency, and health-related quality of life. A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.The AECT is the first valid and reliable patient-reported outcome measure to assess disease control in patients with RA.CONCLUSIONSThe AECT is the first valid and reliable patient-reported outcome measure to assess disease control in patients with RA. |
| Author | Weller, Karsten Zuberbier, Torsten Freier, Denise Magerl, Markus Siebenhaar, Frank Staubach, Petra Donoso, Tamara Krause, Karoline Aygören-Pürsün, Emel Metz, Martin Maurer, Marcus Martinez-Saguer, Inmaculada Altrichter, Sabine Hawro, Tomasz |
| Author_xml | – sequence: 1 givenname: Karsten surname: Weller fullname: Weller, Karsten email: karsten.weller@charite.de organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: karsten.weller@charite.de – sequence: 2 givenname: Tamara surname: Donoso fullname: Donoso, Tamara organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 3 givenname: Markus surname: Magerl fullname: Magerl, Markus organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 4 givenname: Emel surname: Aygören-Pürsün fullname: Aygören-Pürsün, Emel organization: Department of Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany – sequence: 5 givenname: Petra surname: Staubach fullname: Staubach, Petra organization: Department of Dermatology, University Medical Center Mainz, Mainz, Germany – sequence: 6 givenname: Inmaculada surname: Martinez-Saguer fullname: Martinez-Saguer, Inmaculada organization: HRZM Hemophilia Center Rhein Main, Mörfelden-Walldorf, Germany – sequence: 7 givenname: Tomasz surname: Hawro fullname: Hawro, Tomasz organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 8 givenname: Sabine surname: Altrichter fullname: Altrichter, Sabine organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 9 givenname: Karoline surname: Krause fullname: Krause, Karoline organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 10 givenname: Frank surname: Siebenhaar fullname: Siebenhaar, Frank organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 11 givenname: Martin surname: Metz fullname: Metz, Martin organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 12 givenname: Torsten surname: Zuberbier fullname: Zuberbier, Torsten organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 13 givenname: Denise surname: Freier fullname: Freier, Denise organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany – sequence: 14 givenname: Marcus surname: Maurer fullname: Maurer, Marcus organization: Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32173507$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkE9Lw0AQxRep2Fr7BTzIHushcf8k2eQYQtVCoSLBa9hmZ2tKshuzG8Rvb8AKHnyXmcf8eDDvGs2MNYDQLSUhJTR5OIUn2fQhI4yEhIWEpxdowRjlAWOEzv7sc7Ry7kQmpVSQiFyhOWdU8JiIBfp8k22jpG-swVZj_w44N8fGgoJO4sIaP9gWl-A8XueborwPcvwy4WB88Aq9HTwovB99bTvAW-P8MHbTDWs74Nw5cK4xx38ib9Cllq2D1XkuUfm4KYvnYLd_2hb5LqjjOPGBqA-RpoRIFVGdpbXKtMwmlyiZKJVKDkqJGogkXGcAgtOMCUnTOs50WidsidY_sf1gP8bpi6prXA1tKw3Y0VWMC5GkUUzJhN6d0fHQgar6oenk8FX9dsW-AcwOcEw |
| CitedBy_id | crossref_primary_10_1016_j_jaip_2021_08_039 crossref_primary_10_1016_j_jaip_2022_11_016 crossref_primary_10_1111_all_14680 crossref_primary_10_1111_all_15214 crossref_primary_10_1016_j_clim_2025_110542 crossref_primary_10_1016_j_jaci_2025_07_033 crossref_primary_10_29262_ram_v71i4_1323 crossref_primary_10_3389_fneur_2025_1555562 crossref_primary_10_1007_s13555_023_00955_7 crossref_primary_10_7759_cureus_74481 crossref_primary_10_2500_aap_2022_43_210086 crossref_primary_10_3389_fimmu_2024_1413547 crossref_primary_10_1186_s13023_021_01717_4 crossref_primary_10_2302_kjm_2023_0008_IR crossref_primary_10_2478_amma_2024_0009 crossref_primary_10_1001_jamadermatol_2023_5519 crossref_primary_10_1056_NEJMoa2402478 crossref_primary_10_1186_s13023_025_03988_7 crossref_primary_10_1038_s41598_023_47307_1 crossref_primary_10_3389_falgy_2025_1636425 crossref_primary_10_3389_fimmu_2024_1339421 crossref_primary_10_1111_pai_14268 crossref_primary_10_1016_j_jaip_2023_03_006 crossref_primary_10_1016_j_anai_2025_07_025 crossref_primary_10_1186_s13223_021_00537_2 crossref_primary_10_3389_fimmu_2025_1631448 crossref_primary_10_1016_j_jaip_2024_04_056 crossref_primary_10_1038_s41572_022_00389_z crossref_primary_10_1016_j_jaip_2021_04_072 crossref_primary_10_3390_vaccines11020215 crossref_primary_10_5415_apallergy_0000000000000162 crossref_primary_10_1002_clt2_12342 crossref_primary_10_5582_irdr_2025_01045 crossref_primary_10_1007_s12016_021_08843_8 crossref_primary_10_1007_s12016_023_08972_2 crossref_primary_10_1016_j_waojou_2021_100554 crossref_primary_10_1159_000541242 crossref_primary_10_1186_s41687_023_00576_w crossref_primary_10_1016_j_jaci_2023_03_034 crossref_primary_10_1016_j_waojou_2022_100627 crossref_primary_10_1111_all_16563 crossref_primary_10_1111_bjd_19561 crossref_primary_10_3389_fimmu_2025_1550380 crossref_primary_10_1002_clt2_12328 crossref_primary_10_1002_clt2_12295 crossref_primary_10_1111_cea_14527 crossref_primary_10_5415_apallergy_0000000000000172 crossref_primary_10_1016_j_jaip_2025_06_018 crossref_primary_10_1007_s40629_022_00223_8 crossref_primary_10_1016_j_jaip_2024_04_007 crossref_primary_10_1007_s00105_024_05304_z crossref_primary_10_1016_j_jaip_2023_03_032 crossref_primary_10_1111_all_16371 crossref_primary_10_1159_000507218 crossref_primary_10_1016_j_jaip_2024_11_021 crossref_primary_10_5415_apallergy_0000000000000102 crossref_primary_10_1002_clt2_70026 crossref_primary_10_3389_fimmu_2024_1405317 crossref_primary_10_1007_s40257_023_00761_z crossref_primary_10_1007_s15012_024_8542_1 crossref_primary_10_1093_ced_llaf110 crossref_primary_10_1016_j_jaip_2023_04_017 crossref_primary_10_1016_j_jaci_2021_05_016 crossref_primary_10_2500_aap_2025_46_250025 crossref_primary_10_1007_s12016_021_08841_w crossref_primary_10_1016_j_jaip_2024_08_021 crossref_primary_10_1016_j_jaip_2021_02_026 crossref_primary_10_1093_skinhd_vzaf055 crossref_primary_10_1016_j_jacig_2023_100087 crossref_primary_10_1016_j_jaip_2025_07_008 crossref_primary_10_1016_j_waojou_2021_100610 crossref_primary_10_1007_s15007_022_5601_y crossref_primary_10_1016_j_anai_2023_03_028 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jaip.2020.02.038 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-2201 |
| ExternalDocumentID | 32173507 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | .1- .FO 0R~ 1P~ 4.4 457 53G 8FH AAEDT AAEDW AAFWJ AALRI AAXUO ABLJU ACGFS ACPRK ADBBV AEVXI AFJKZ AFRHN AFTJW AGCQF AHMBA AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP BELOY BKEYQ BVXVI CGR CUY CVF EBS ECM EFJIC EFKBS EIF EJD FDB HZ~ KOM LK8 NPM O9- O9~ OK0 PQQKQ PROAC ROL WOW Z5R 7X8 |
| ID | FETCH-LOGICAL-c556t-7cb4f100ad41f98cd9fa90ad6da6dd8a3edd7ce0a03f9ee731927a18c59f8c62 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 83 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000565646000037&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2213-2201 |
| IngestDate | Sun Sep 28 07:38:23 EDT 2025 Mon Jul 21 05:59:30 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Validation Screening Validity Control test Angioedema Cutoff Development Patient-reported outcome Reliability Disease control |
| Language | English |
| License | Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c556t-7cb4f100ad41f98cd9fa90ad6da6dd8a3edd7ce0a03f9ee731927a18c59f8c62 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32173507 |
| PQID | 2377684510 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2377684510 pubmed_primary_32173507 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-01 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
| PublicationTitleAlternate | J Allergy Clin Immunol Pract |
| PublicationYear | 2020 |
| SSID | ssj0000817040 |
| Score | 2.4734561 |
| Snippet | Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2050 |
| SubjectTerms | Angioedema - diagnosis Humans Patient Reported Outcome Measures Psychometrics Quality of Life Reproducibility of Results Surveys and Questionnaires |
| Title | Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32173507 https://www.proquest.com/docview/2377684510 |
| Volume | 8 |
| WOSCitedRecordID | wos000565646000037&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhIDDBaJHSfOhKqKCiRaOkRVt8rxAxWJpNAW_j7nOIUFJCSWRBmcWL7z3Ze783cIXajcaq7iiIA25CTS1hJhU0EEt5waC7eKnX_wkPR6YjhM-3XAbVqXVS5sYmWodalcjPyassTljECFbiavxHWNctnVuoXGMmowgDJOq5Oh-IqxBI59rjoTSWnICAVnV5-b8SVez3LsKCtpUNF2MvE7yqy8TWfzv_PcQhs1zsQtrxjbaMkUO2itW2fSd9HHAAC476eES4sBBuJW8TQujTYvErd9ATvO4Lv4snXbzq5IC_c9ByvxoN1o_DifwaQMvq9oaF2cEQMGxj6RDD7xh1fuoaxzm7XvSN2EgSjO4xlJVB7ZMAikjkIQotKplSk8xVrGWgvJjNaJMoEMmE2NSWBL00SGQvHUChXTfbRSlIU5RFhILgE8gVWTeRSLOA8YoymXOsyt0TxtovPFio5Ax13iQhamnE9H32vaRAdeLKOJJ-MYMfinYgBqj_4w-hitO2n7Sq8T1LCww80pWlXvs_H07axSHrj2-t1P7gbP4g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+the+Angioedema+Control+Test+%28AECT%29-A+Patient-Reported+Outcome+Instrument+for+Assessing+Angioedema+Control&rft.jtitle=The+journal+of+allergy+and+clinical+immunology+in+practice+%28Cambridge%2C+MA%29&rft.au=Weller%2C+Karsten&rft.au=Donoso%2C+Tamara&rft.au=Magerl%2C+Markus&rft.au=Ayg%C3%B6ren-P%C3%BCrs%C3%BCn%2C+Emel&rft.date=2020-06-01&rft.eissn=2213-2201&rft.volume=8&rft.issue=6&rft.spage=2050&rft_id=info:doi/10.1016%2Fj.jaip.2020.02.038&rft_id=info%3Apmid%2F32173507&rft_id=info%3Apmid%2F32173507&rft.externalDocID=32173507 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-2201&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-2201&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-2201&client=summon |